New clinical parameters in chronic obstructive pulmonary disease;Nuevos parámetros clínicos en la EPOC

Archivos de Bronconeumologia

Volumn 44, Issue SUPPL. 2, 2008, Pages 4-10

  Izquierdo Alonso, José Luis ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Clinical parameters; COPD; Mortality; Progression

Indexed keywords

ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; DETERIORATION; DISEASE CONTROL; DISEASE EXACERBATION; EARLY DIAGNOSIS; EXERCISE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CANCER; LUNG FUNCTION; MORTALITY; PRACTICE GUIDELINE; RESPIRATORY FUNCTION; REVIEW; SYMPTOM; VASCULAR DISEASE;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 58149506168     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Disponible: www.goldcopd.com
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
3. Perpiñá Tordera M, Martínez Francés M. Disnea: bases fisiopatológicas, medición e implicaciones en la rehabilitación. En: Güell R, De Lucas, P, editores. Rehabilitación respiratoria. Madrid: MMC; 1999.
4. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434-40.
5. American Thoracic Society. Dyspnea: mechanisms, assessment and management: a consensus statement. Am J Respir Crit Care Med. 1999;159:321-40.
6. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347-60.
7. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23:28-33.
8. McKenzie DK, Frith PA, Burdon JG, Town GI; Australian Lung Foundation; Thoracic Society of Australia and New Zealand.The COPDX plan: Australian and New Zealand guidelines for de management of chronic obstructive pulmonary disease 2003. Med J Aust. 2003;178:S1-S37.
9. Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol. 2008;44:271-81.
10. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-505.
11. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-9.
12. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;133:14-20.
13. Van den Boom G, Rutten-van Molken MP, Tirimanna PR, Van Schayck CP, Folgering H, Van Weel C. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J. 1998;11: 67-72.
14. De Miguel Díez J, Izquierdo Alonso JL, Rodríguez González Moro JM, De Lucas Ramos P, Molina París J. Calidad de vida en la enfermedad pulmonar obstructiva crónica. Influencia del nivel de asistencia de los pacientes. Arch Bronconeumol. 2004;40:431-7.
15. Ferrer M, Alonso J. Medición de la calidad de vida en los pacientes con EPOC. Arch Bronconeumol. 2001;37 Supl 2:20-6.
16. Van der Molen T, Willense BWM, Schokker S, Ten Hacken NHT, Postma DS, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes. 2003;1:13.
17. Kocks JWH, Tuinenga MG, Uil SM, Van den Berg JWK, Stahl E, Van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006;7:62.
18. García Río F, Lores V, Rojo B. Evaluación funcional respiratoria (obstrucción y atrapamiento). Arch Bronconeumol. 2007;43 Supl 3:8-14.
19. Casanova C, Cote C, De Torres JP, Aguirre-Jaime A, Marín JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591-7.
20. Marín JM, Carrizo SJ, Gascón M, Sánchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163:1395-9.
21. Izquierdo JL, Almonacid C, Parra T, Pérez J. Inflamación y estrés oxidativo en dos fenotipos de EPOC. Arch Bronconeumol. 2006; 42:332-7.
22. Izquierdo Alonso JL, Sánchez Hernández I, Fernández Francés J, Castelao Naval J, Carrillo Arias F, Gallardo Carrasco J. Utility of transfer factor to detect different bronchofilator responses in patients with COPD. Respiration. 1998;65:282-8.
23. Weir DC, Gove IR, Robertson AS, Sherwood PB. Response to costicosteroids in chronic airflow obstruction: relationship to emphysema and airways collapse. Eur Respir J. 1991;4:1185-90.
24. Eliasson O, Degraff AC. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Am Rev Respir Dis. 1985;132:858-64.
25. Witzenblum E, Chaouat A. Severe pulmonary hipertensión in COPD. Is it a distinct disease? Chest. 2005;127:1480-2.
26. Gelb AF, Schein M, Kuei J, Tashkin DP, Müller NL, Hogg JC, et al. Limited contribution of emphysema in advanced chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;147:1157-61.
27. Hogg JC, Wright JL, Wiggs BR, Coxson HO, Opazo Saez A, et al. Lung structure and function in cigarette smokers. Thorax. 1994; 49:473-8.
28. Köhnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med. 2008; 121:3-9.
29. Weder W, Thurnheer R, Stammberg U. Radiologic emphysema morphology is associated with outcome after surgical lung volume reduction. Ann Thorac Surg. 1997;64:313-20.
30. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21:892-905.
31. Peinado VI, Barberà JA, Ramírez J, Gómez FP, Roca J, Jover L, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol Lung Cell Mol Physiol. 1998;18: L908-L13.
32. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172: 189-94.
33. Thabut G, Dauriat G, Stern JB, Logeart D, Lévy A, Marrash-Chahla R, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531-6.
34. Izquierdo JL, De Miguel J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. J COPD. 2004;1:215-23.
35. Connors AF, Dawson NV, Thomas C, Harrel FE Jr, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease: the SUPPORT investigators. Am J Respir Crit Care Med. 1996;154:959-67.
36. Senneff MG, Wagner DP, Wagner RP. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274:1852-7.
37. Domingo-Salvany A, Lamarca R, Ferrer M, García-Aymerich J, Alonso J, Félez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respire Crit Care Med. 2002;166:680-5.
38. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925-31.
39. Celli BR, Cote CG, Marín JM, Casanova C, Montes de Oca M, Méndez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005-12.
40. Soler JJ, Sánchez L, Román P, Martínez MA, Perpiñá M. Prevalencia de desnutrición en pacientes con EPOC estable. Arch Bronconeumol. 2004;40:250-8.
41. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2006;19:189-99.
42. Man P, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849-53.
43. Sin DD, Man SFP, McWillimas A, Lam S. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Critical Care Med. 2006;173:535-9.
44. Izquierdo JL, Arroyo-Espliguero R. EPOC y riesgo cardiovascular. Arch Bronconeumol. 2005;41:410-2.
45. Tall AR. C-reactive protein reassessed. N Engl J Med. 2004;350: 1450-2.
46. Lucas-Ramos P, Izquierdo-Alonso JL, Rodríguez-González Moro JM, Bellón-Cano JM, Ancochea-Bermúdez J, Calle-Rubio M, et al. Asociación de factores de riesgo cardiovascular y EPOC. Resultados de un estudio epidemiológico (estudio ARCE). Arch Bronconeumol. 2008;238:233-8.
47. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. En prensa 2008.
48. García-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007; 175:458-63.
49. Lin K, Watkins B, Johnson T, Rodríguez JA, Barton MB. Screening for chronic obstructive pulmonary disease using spiroemtry: summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2008;148:535-43.
50. Barreiro E, Schols AM, Polkey MI, Gáldiz JB, Gosker HR, et al; ENIGMA in COPD project. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008;63:100-7.